AbbVie Inc. (TSX:ABBV)

Canada flag Canada · Delayed Price · Currency is CAD
30.72
-0.80 (-2.54%)
At close: Jan 28, 2026
20.57%
Market Cap524.72B
Revenue (ttm)83.08B +7.4%
Net Income3.27B -53.4%
EPS1.84 -54.0%
Shares Outn/a
PE Ratio160.44
Forward PE16.69
Dividend0.95 (3.00%)
Ex-Dividend DateJan 16, 2026
Volume5,558
Average Volume4,265
Open31.49
Previous Close31.52
Day's Range30.57 - 31.49
52-Week Range23.68 - 34.48
Betan/a
RSI45.39
Earnings DateFeb 4, 2026

About AbbVie

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancer... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2012
Employees 55,000
Stock Exchange Toronto Stock Exchange
Ticker Symbol ABBV
Full Company Profile

Financial Performance

In 2024, AbbVie's revenue was $56.33 billion, an increase of 3.71% compared to the previous year's $54.32 billion. Earnings were $4.24 billion, a decrease of -12.07%.

Financial numbers in USD Financial Statements